Pharmacological modulators that can coactivate TrkB signaling-mediated cell survival and Nrf2-ARE antioxidant systems offer promise for the treatment of diseases associated with OS-associated brain degeneration. This evidence concerns the gene NTRK2 and neurodegenerative disease.